All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Clonidine
Therapeutic Area: Gastroenterology Product Name: Validive
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Patent provide claims covering “Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy”.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Filgotinib
Therapeutic Area: Gastroenterology Product Name: Jyseleca
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
The EMA application is supported by data from the Phase 2b/3 SELECTION study, which showed a statistically significantly higher proportion of patients treated with once-daily filgotinib 200 mg achieved clinical remission at week 10 and maintained remission at week 58.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Noroxymorphone analogs
Therapeutic Area: Gastroenterology Product Name: CYTO-201
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Cleveland BioLabs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 20, 2020
Details:
Merger to create a single public company focused on the development and commercialization of immunotherapies for oncology, infectious disease, inflammation and auto-immune mediated conditions. Portfolio includes investigational drug, CYTO-201, for COVID-19 infection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Guselkumab
Therapeutic Area: Gastroenterology Product Name: Tremfya
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
At 12 weeks, TREMFYA induced significantly greater improvements compared to placebo across key clinical and endoscopic outcome measures, with a safety profile consistent with approved indications.1 TREMFYA is not currently approved for the treatment of CD in the U.S.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Filgotinib
Therapeutic Area: Gastroenterology Product Name: Jyseleca
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
Filgotinib 200mg Achieved Endoscopic, Histologic and Six-Month Corticosteroid-Free Remission at Week 58 with a Consistent Safety Profile.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Brazikumab
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination May 11, 2020
Details:
AstraZeneca and Allergan have terminated their previous license agreement and all rights to brazikumab have therefore now returned to AstraZeneca.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Brazikumab
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment January 27, 2020
Details:
AstraZeneca will acquire brazikumab, in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Galacto-oligosaccharide
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Qualigen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger January 21, 2020
Details:
The merged company will focus on the development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases, while also continuing to operate its profitable diagnostic business.